Hormone Therapy | malecare.org

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC) usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

By Malecare|2018-02-05T18:25:03-05:00February 7th, 2018|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Hormone Therapy, Research, Understanding APC|0 Comments

Metastatic Prostate Cancer – Bone Metastases Might Be Controled With Xofigo For Two or More Years

Metastatic Prostate Cancer suffers have good news. Xofigo, also known as Radium-223 (Ra-223), is a treatment for patients with castration-resistant prostate cancer (CRPC) and symptomatic (you can feel them) bone metastases (mets). Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on [...]

By Malecare|2018-02-06T11:09:18-05:00February 5th, 2018|Advanced Prostate Cancer, Hormone Therapy|0 Comments

Androgen Deprivation Therapy (ADT) may not be the best way to fight advanced prostate cancer

Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate [...]

By Malecare|2020-02-04T11:27:36-05:00March 15th, 2017|Advanced Prostate Cancer, Hormone Therapy, Uncategorized|0 Comments

Relugolix – Oral Hormone Treatment for advanced prostate cancer

There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and [...]

By Malecare|2017-04-26T09:16:16-04:00March 2nd, 2017|Advanced Prostate Cancer, Hormone Therapy, Uncategorized|1 Comment

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]

By Malecare|2020-02-04T10:20:15-05:00November 29th, 2016|ADT, Advanced Prostate Cancer, cognitive deficiits, Drugs & Treatments, Hormone Therapy, Quality of Life, Side Effects, Uncategorized, Understanding APC|0 Comments